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Abstract
Background: Glucocorticoids (GCs) control expression of a large number of genes via binding to the GC receptor (GR). 
Transcription may be regulated either by binding of the GR dimer to DNA regulatory elements or by protein-protein 
interactions of GR monomers with other transcription factors. Although the type of regulation for a number of 
individual target genes is known, the relative contribution of both mechanisms to the regulation of the entire 
transcriptional program remains elusive. To study the importance of GR dimerization in the regulation of gene 
expression, we performed gene expression profiling of livers of prednisolone-treated wild type (WT) and mice that 
have lost the ability to form GR dimers (GRdim).
Results: The GR target genes identified in WT mice were predominantly related to glucose metabolism, the cell cycle, 
apoptosis and inflammation. In GRdim mice, the level of prednisolone-induced gene expression was significantly 
reduced compared to WT, but not completely absent. Interestingly, for a set of genes, involved in cell cycle and 
apoptosis processes and strongly related to Foxo3a and p53, induction by prednisolone was completely abolished in 
GRdim mice. In contrast, glucose metabolism-related genes were still modestly upregulated in GRdim mice upon 
prednisolone treatment. Finally, we identified several novel GC-inducible genes from which Fam107a, a putative 
histone acetyltransferase complex interacting protein, was most strongly dependent on GR dimerization. 
Conclusions: This study on prednisolone-induced effects in livers of WT and GRdim mice identified a number of 
interesting candidate genes and pathways regulated by GR dimers and sheds new light onto the complex 
transcriptional regulation of liver function by GCs.
Background
Naturally occurring glucocorticoids (GCs), such as corti­
sol, play an important role in the regulation of cardiovas­
cular, metabolic and immunological processes. GCs are 
potent suppressors of inflammatory indices and are 
widely used to treat chronic inflammatory diseases such 
as rheumatoid arthritis and asthma [1-3]. However, 
chronic use of GCs induces side effects, such as diabetes 
mellitus, fat redistribution, osteoporosis, muscle atrophy, 
glaucoma and skin thinning [4].
One of the aspects influencing the balance between the 
desired anti-inflammatory effects and the side effects of
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GCs is the activation and repression of gene expression. 
After binding of GCs to the cytosolic GC receptor (GR), 
the receptor-ligand complex translocates to the nucleus 
where it alters gene expression. Ligand-bound GR can 
influence the expression of target genes, either by binding 
as a dimer to palindromic GC response elements (GRE) 
or tethering to other DNA-bound transcription factors 
[5,6].
It is generally assumed that the anti-inflammatory 
actions of GCs are mainly driven by transrepression, in 
which ligand-bound GR binds to the pro-inflammatory 
transcription factors NF-kB (Nuclear factor kappa-light- 
chain-enhancer of activated B cells), AP-1 (Activator pro­
tein 1), IRF-3 (Interferon regulatory factor 3) or other fac­
tors, forming an inactive transcription machinery
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complex, which prevents expression of pro-inflammatory 
genes [7-16]. However, recent studies demonstrated that 
under some inflammatory conditions DNA dimer-depen­
dent gene expression could also contribute to the anti­
inflammatory activities of the GR [17]. The occurrence of 
side effects has been linked mainly to transactivation of 
gene transcription. The well-documented example of 
GC-induced upregulation of Pck1 (Phosphoenolpyruvate 
carboxykinase 1; also known as Pepck) and G6pc (Glu- 
cose-6-phosphatase), two genes encoding key enzymes 
that control gluconeogenesis, is one example linking 
transactivation to metabolic side effects [18-20].
One of the mechanisms by which GR activates gene 
transcription is by binding as a homodimer to a GRE in 
the promoter region of a target gene. GR dimerization 
involves the D loop located in the DNA-binding domain 
of the GR, in which several amino acids interact to facili­
tate receptor dimer formation. It was shown that an 
A458T point mutation, introduced in the D loop of the 
GR (GRdim), impairs homodimerization and ablates DNA 
binding [21]. Mice carrying this GRdim mutation are 
almost as effective as wild type (WT) mice in repressing 
AP-1 and NF-KB-modulated gene transcription, whereas 
GR-mediated Tat (Tyrosine aminotransferase) mRNA 
induction is largely abolished [21,22].
The mechanism of dimer-dependent transactivation by 
the GR has been studied in detail for a limited number of 
GR target genes, including Fkbp5 (FK506 binding protein 
5), Tat, Pck1 and Dusp1 (Dual specificity phosphatase 1) 
[23-26], and tethering-facilitated transrepression of 
Mmp1/Mmp13 (Matrix metallopeptidase 1/13), IL-8 
(Interleukin 8) and others [27-29]. In order to perform a 
comprehensive study of the genes and cellular processes 
that are affected by GC-treatment and influenced by GR 
dimerization, we have performed genome wide gene 
expression profiling in liver of prednisolone-treated WT 
and GRdim mice.
We found that prednisolone predominantly influenced 
expression of genes involved in glucose metabolism, 
inflammation, the cell cycle and apoptosis. In general, 
activation of transcription, including transactivation of 
known GR marker genes such as Fkbp5 and Tat, was sig­
nificantly reduced, but not totally absent in the GRdim 
mutant. However, a total absence of transcriptional trans­
activation upon GC-treatment was observed in GRdim 
mice for a subset of genes, all related to regulation of the 
cell cycle. In contrast, a small subset of genes was found 
exclusively regulated by GCs in GRdim mice. Furthermore, 
we identified Fam107a (Family with sequence similarity 
107, member a; also known as Tu3a and Drr1) as a novel 
GC-inducible gene that completely relies on GR 
dimerization for transactivation.
Results
Clustering of individual samples
In order to chart the gene expression profile induced by 
prednisolone in WT and GRdim mice, 6 mice per group 
were treated with prednisolone or vehicle. A principal 
component analysis (PCA) on the normalized intensity 
data showed that the samples clustered into four distinct 
groups (Figure 1). The largest separation, represented by 
PC1, was observed between samples derived from male 
versus female mice. The genes with the highest gender 
specificity belong to the family of cytochrome P450 pro­
teins, such as Cyp3a41, Cyp3a44 and Cyp4a12, which are 
known for their gender-specific expression [30,31]. In 
addition to the gender-based separation, a clear separa­
tion was observed between prednisolone-treated and 
vehicle-treated WT mice, whereas prednisolone-treated 
GRdim mice clustered closely together with vehicle- 
treated GRdim and WT mice (PC2). These results indicate 
that there is a significant prednisolone effect in W T mice, 
which is strongly reduced in prednisolone-treated GRdim 
mice. Genes with high loading scores on PC2 include Tat 
and Fkbp5, which are known GR-regulated genes in liver 
[32,33] (Figure 2).
These results show that the transcriptional program 
that is induced by prednisolone in WT mice is strongly 
reduced in mice carrying the GRdim mutation. This sup-
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F ig u re  1 P rin cipal co m p o n en t a na lysis on gen e e xp ressio n  in te n ­
sity data. A principal com ponent analysis (PCA) was performed on 
normalized gene expression intensity data from 12 wild type (WT) mice 
(vehicle and prednisolone treatment) and 12 GRdim mice (vehicle and 
prednisolone treatment). Bullets: WT mice; Triangles: GRdim mice. White 
symbols: vehicle-treated mice; Black symbols: prednisolone-treated 
mice. The largest separation was seen between samples derived from 
male versus female mice (PC1).
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F ig u re  2 In ten sity  p ro file s o f Tat and F k b p5 in veh ic le  and p re d n i­
solone-treated w ild  type v e rsu s GRdim mice. The expression intensi­
ties of Tat (Tyrosine aminotransferase) and Fkbp5 (FK506 binding protein 
5) in vehicle-treated (white bars) and prednisolone-treated (grey bars) 
wild type (WT) and GRdim mice are plotted. Symbols: Bullets: male mice; 
Triangles: female mice. Both Tat and Fkbp5 are known GR marker genes 
and show strong differential regulation in prednisolone-treated WT 
mice.
ports the hypothesis that the loss of GR dimerization 
leads to a reduction in transcriptional transactivation by 
the GR and underscores the importance of GR dimeriza­
tion in induction of gene expression. The effect of predni­
solone on up and downregulated genes and pathways will 
be discussed in more detail below.
Prednisolone-induced changes in gene expression
To quantify the differences that were seen in the multi­
variate analysis, differentially expressed probe sets were 
identified for several treatment comparisons (e.g. predni­
solone versus vehicle-treated W T mice and prednisolone 
vs. vehicle-treated GRdim mice). Probe sets were marked 
as differentially regulated when the p -value, corrected for 
multiple testing, was below the 0.01 cutoff value.
Prednisolone treatment resulted in a significant differ­
ential regulation of 518 probe sets in WT mice (347 
upregulated and 171 downregulated; Additional file 1), 
whereas in prednisolone-treated GRdim mice only 34 
probe sets were differentially regulated (29 upregulated 
and 5 downregulated; Additional file 2). Notably, no dif­
ferentially regulated probe sets were found in the com­
parison between vehicle-treated GRdim and vehicle- 
treated WT mice, suggesting that the GRdim mutation 
itself does not cause differential gene regulation and that 
the effects between W T and GRdim mice only become 
apparent after treatment with prednisolone.
The observation that only 34 probe sets are differen­
tially regulated in GRdim mice upon prednisolone treat­
ment, suggests that there is almost no regulation of gene 
expression by prednisolone in GRdim mice. However, a 
large number of the probe sets that are differentially reg­
ulated in WT mice showed the same direction of regula­
tion by prednisolone in GRdim mice, but did not meet the 
cutoff value of 0.01 for the p-value. This indicates that 
induction of gene expression by prednisolone in GRdim 
mice is strongly reduced but not completely absent (see 
below).
Taken together these data are in line with the hypothe­
sis that transactivation of gene expression through the 
GR is significantly reduced in mice carrying the GRdim 
mutation.
Biological processes targeted by prednisolone in WT mice
In order to identify cellular processes on which predniso­
lone has a prominent effect, a gene set enrichment analy­
sis was conducted using the 518 probe sets that were 
differentially regulated in WT mice by prednisolone. For 
this analysis we used CoPub, a text mining tool that cal­
culates which biological processes are significantly asso­
ciated to a set of genes [34]. It appeared that the 
differentially regulated genes are predominantly involved 
in three major processes: (glucose) metabolism, cell 
cycle/apoptosis and immune/inflammatory response 
(Table 1).
In order to gain insight into the relationships between 
genes and cellular processes a network representation 
was created, in which differentially regulated genes are 
plotted together with enriched keywords. In this repre­
sentation, cellular processes that are affected by predni­
solone can be appreciated as separate areas in the 
network, such as cell cycle and apoptosis, acute-phase 
response, and metabolism-related processes such as 
amino acid metabolism, gluconeogenesis and lipid 
metabolism. The most influential genes appear as highly 
connected hubs (Figure 3). Important factors that seem 
to connect the gluconeogenesis and the cell cycle and 
apoptosis subnetworks are the transcription factors 
Foxo1 and Foxo3a (Forkhead box O1 and Forkhead box 
O3a; see below).
Strong effects of prednisolone treatment on gluconeo- 
genesis, the cell cycle and apoptosis are in line with the 
anticipated effect of the GR in the liver. The fact that 
many inflammation and acute phase response-related 
genes, such as IL6r (Interleukin 6 receptor) and Cxcl12 
(Chemokine (C-X-C motif) ligand 12) were regulated (Fig­
ure 3) is interesting, given that we analyzed livers from 
healthy mice, not challenged with inflammatory stimuli. 
The direction and magnitude of prednisolone-induced 
differential regulation of genes involved in gluconeogene- 
sis and the cell cycle was studied in more detail to get 
more insight into these prednisolone-affected processes.
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Table 1: CoPub keyword enrichment analysis on 
prednisolone-regulated genes.
B io lo g ica l p ro ce ss # o f  a sso cia te d  g e n es
M e ta b o lism
G lucose m etabolism /transport 22
G luconeogenesis 21
Lipid m etabolism /glycosylation 21
Glycolysis 14
Carbohydrate m etabolism / 
transport
14
Am ino acid m etabolism /transport 13
C ell cy cle  a n d  a p o p to sis
A poptosis 77
Cell proliferation 72
Cell cycle 65
Cell grow th and-or m aintenance, 
cell growth
63
Homeostasis 58
Cell differentiation 49
Cell cycle arrest 37
Im m u n e /in fla m m a to ry  re sp o n se
Inflam m atory response 31
Acute-phase response 20
C oPub was used to calculate keyword enrichm ent in the set of 
prednisolone-regulated probe sets in wild type mice. The
analysis revealed that the differential regulated genes (non­
redundant set) are predom inantly involved in three main 
processes: metabolism, cell cycle and apoptosis, and im m une/ 
inflammatory response. The right colum n shows the num ber of 
differential regulated genes associated with a specific enriched 
keyword.
Gluconeogenesis
Table 2 shows the prednisolone-regulated genes in WT 
mice identified by CoPub as being associated with gluco- 
neogenesis. Among the upregulated genes are Pck1, 
encoding the rate limiting enzyme in gluconeogenesis 
[35], Ppargc1a (Peroxisome proliferative activated recep­
tor, gamma, coactivator 1 alpha), a transcriptional coacti­
vator that coordinates the expression of genes involved in 
gluconeogensis and ketogenesis [36], and Sds (Serine 
dehydratase) and Aass (Aminoadipate-semialdehyde syn­
thase), two genes encoding enzymes involved in amino 
acid catabolism and amino acid utilization for gluconeo- 
genesis [37,38].
The set of downregulated genes includes Irs1 (Insulin 
receptor substrate 1), a downstream mediator of the
growth factor/insulin signaling pathway that negatively 
regulates gluconeogenesis [39] and Pklr (Pyruvate 
kinase), which encodes a glycolysis associated enzyme 
known to catalyze the production of pyruvate from phos- 
phoenolpyruvate [40].
The direction of regulation and the function of these 
genes, suggests that in the liver of prednisolone-treated 
WT, glucose metabolism is balanced towards gluconeo- 
genesis, which is in line with the reported gluconeogenic 
effect of glucocorticoids [41,42]. The reduced fold 
changes in GRdim mice compared to WT mice (Table 2) 
indicate that glucocorticoid-induced gluconeogenesis is 
reduced in GRdim mice.
Cell cycle
Table 3 shows the prednisolone-regulated genes in WT 
mice that CoPub identified as being associated with the 
cell cycle. Upregulated genes include Gadd45b, Gadd45g 
(Growth arrest and DNA-damage-inducible 45 beta and 
gamma), Cdkn1a (Cyclin-dependent kinase inhibitor 1a; 
also known as p21) and Plk3 (Polo-like kinase 3), which 
are stress sensors involved in cell cycle arrest, DNA repair 
and apoptosis [43-45]. Other upregulated genes are 
Bcl2l1 (also known as Bcl2-like1 and Bcl-xl), an anti- 
apoptotic protein that is enhanced by binding to the 
Gadd45 family [46,47], and Dusp1, a p53 target gene 
involved in cell cycle regulation [48].
Amongst the downregulated genes are Ccnd2 (Cyclin 
D2) and Cks2 (Cdc28protein kinase regulatory subunit 2), 
both involved in cell cycle progression [49,50]. Overall, 
the direction of the prednisolone-induced differential 
regulation of genes associated with the cell cycle suggests 
that prednisolone induces a cytostatic response in liver of 
WT mice.
Foxo transcription
From the literature-based network, the two transcription 
factors Foxo1 and Foxo3a appear to be intermediates 
between the gluconeogenesis and cell cycle and apoptosis 
subnetworks (Figure 3). Foxo transcription factors are key 
mediators of cell cycle progression, apoptosis, glucose 
metabolism, reactive oxygen species detoxification and 
DNA damage repair [51-54]. Their activity is tightly con­
trolled by the insulin and growth factor-inducible Pi3k/ 
Akt pathway. Akt-mediated phosphorylation of Foxo 
transcription factors promotes their translocation from 
the nucleus to the cytosol and thereby their inactivation 
through binding of 14-3-3 proteins [54-56].
Foxo transcription factors regulate gene expression of 
enzymes that are important regulators of gluconeogene- 
sis, such as Pck1 and G6p  [57,58]. In addition, they sup­
press genes that are involved in glycolysis, the pentose 
shunt and lipogenesis [59]. Analysis of Foxo1-overex- 
pressing mice revealed an increased expression of Igfbp1
Frijters et al. BMC Genomics 2010, 11:359
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F ig u re  3 Literature-based n etw o rk o f g lu co co rtico id -in d u ce d  effects. A network representation of the enrichment results was generated, in 
which differentially expressed genes together with enriched keywords are plotted. Genes are shown as circles (Red: upregulated; Green: downregu- 
lated), whereas enriched keywords are shown as squares. Connections between genes and keywords represent co-publications in Medline abstracts. 
To avoid an over-complex network, thresholds were set to simplify the interpretation of the results. Only keywords and genes that share at least 5 
publications and have an fi-scaled score of at least 45 are plotted in the network [34]. Several higher-order biological processes that are affected by 
prednisolone can be appreciated: cell cycle and apoptosis, acute-phase response, stress response, amino acid metabolism, gluconeogenesis and lipid 
metabolism.
(Insulin-like growth factor binding protein 1), Pck1, Tat 
and Tdo (Tryptophan 2,3-dioxygenase) and downregula- 
tion of Srebf1 (Sterol regulatory element binding factor 1) 
and Adipor2 (Adiponectin receptor 2) in liver [59]. Inter­
estingly, these genes are similarly regulated in predniso­
lone-treated WT mice (Figure 3 and Table 2).
Finally, Foxo transcription factors are regulators of cell
cycle progression and were shown to induce Cdkn1a and 
Gadd45b [60] and to suppress Ccnd2 [54]. Also these 
genes show the same direction of regulation in predniso­
lone-treated WT mice (Figure 3 and Table 3). These 
observations suggest that GCs in WT mice induce Foxo 
transcription factors, which in turn may synergize with 
the GR to modulate the expression of their respective tar­
get genes.
Prednisolone-induced differential gene expression in WT 
versus GRdim mice
Table 2 and 3 list a number of genes that are significantly 
regulated by prednisolone in W T mice. In the GRdim mice 
these genes do not meet the significance cutoff for differ­
ential regulation (p < 0.01), but for most of them a small 
effect of prednisolone on the expression level can be 
observed in GRdim mice. To analyze these differences 
quantitatively, we plotted the log2 ratios of gene expres­
sion after prednisolone treatment in WT versus GRdim 
mice (Figure 4). This figure shows that on average, genes 
in WT mice are more strongly regulated than in GRdim 
mice after prednisolone treatment and confirms that 
induction of gene expression by prednisolone is not abro­
gated in GRdim mice but reduced to on average 33% of the
Frijters et al. BMC Genomics 2010, 11:359
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Table 2: Prednisolone-regulated genes associated with 'gluconeogenesis' in literature.
B io lo g ica l pro ce ss: g lu c o n e o g e n e sis
G en e  nam e Sym bo l Fc W T Fc GRdim *
Insulin-like grow th factor binding protein l Ig fb p l 9.7 3.6
Tyrosine am inotransferase Tat 4.1 1.6
6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 Pfkfb3 3.9 2.3
Peroxisom e proliferative activated receptor, gam m a, coactivator l alpha Ppargc l a 3.2 3.2
CCAAT/enhancer b inding protein (C/EBP), beta Cebpb 3.1 1.6
Protein-tyrosine sulfotransferase 2 Tpst2 2.7 1.5
Solute carrier fam ily 2 (facilitated glucose transporter), m em ber l Slc2a l 2.6 1.9
Forkhead b o x  O l F o xo l 2.2 1.7
Serine dehydratase Sds 2.1 1.5
A m inoadipate-sem ialdehyde synthase Aass 2.1 1.3
P hosphoenolpyruvate carboxykinase l, cytosolic P ckl 1.9 1.3
Tryptophan 2,3-dioxygenase Tdo2 1.5 1.2
Aconitase 2, m itochondrial A co2 1.4 1.3
Transketolase Tkt -1.2 -1.1
Protein kinase, AMP-activated, beta l non-catalytic subunit P rka bl -1.5 1
Adiponectin receptor 2 A dipor2 -1.6 -1.3
Purinergic receptor P2Y, G-protein coupled, 5 P2ry5 -1.6 -1.3
Pyruvate kinase liver a nd red blo od  cell Pklr -2.1 -1.4
CCAAT/enhancer b inding protein (C/EBP), alpha Cebpa -2.3 -1.2
Sterol regulatory elem ent binding factor l S rebfl -3 -1.6
Insulin receptor substrate l Irs l -4 -1.5
C oPub identified 21 prednisolone-regulated genes in w ild type (WT) m ice that are associated in literature with gluconeogenesis. The 
identified genes share at least 3 publications and have an fi-scaled score [34] of at least 35 with keyword 'gluconeogenesis' in M edline 
abstracts. For each gene, the fold change (Fc) in prednisolone versus vehicle-treated WT mice (Fc WT) is given. Additionally, for each gene 
also the Fc in prednisolone versus vehicle-treated GRdim m ice (Fc GRdim) is shown. *It should be noted that in GRdim m ice these genes did not 
meet the p-value cutoff o f 0.01 for significance after correction for m ultiple testing, and are m entioned to illustrate a small effect of 
prednisolone on gene expression in GRdim mice.
level in WT mice, as indicated by the slope of the dotted 
line in Figure 4.
Identification of genes that differentially respond to 
prednisolone in GRdim mice as compared to WT mice
In Figure 4, several genes are highlighted that show a dif­
ferent response upon prednisolone treatment in WT 
mice than in GRdim mice.
Unexpectedly, a small subset of these genes shows 
stronger upregulation by prednisolone in GRdim mice 
compared to WT mice. These genes include Car8 (Car­
bonic anhydrase 8), a protein associated with prolifera­
tion and invasiveness of colon cancer cells [61], Zdhhc23 
(Zinc finger, DHHC-type containing 23), a Nitric oxide 
synthase-binding and activation protein [62], Flvcr2 
(Feline leukemia virus subgroup C cellular receptor family, 
member 2), a calcium-chelate transporter [63], and Amy2
(Amylase 2), an amylase that catalyzes the endohydrolysis 
of 1,4-alpha-D-glucosidic linkages in oligosaccharides.
Genes that appear to strictly rely on GR dimerization 
include Dusp1, Gadd45b, Cdkn1a, Foxo3a, Plk3 and 
Fam107a (Figure 4 and 5). As discussed above, Foxo3a, 
Dusp1, Gadd45b, Cdkn1a and Plk3 all participate in cell 
cycle regulation, apoptosis and DNA damage repair [43­
45,52]. The most striking difference in the level of regula­
tion by prednisolone between WT and GRdim mice was 
observed for Fam107a (also known as Tu3a and Drr1) 
(Figure 4, 5 and 6). The expression profile suggests that 
transcription of Fam107a is under direct control of the 
GR and strictly depends on its dimerization. Fam107a 
encodes a ubiquitously expressed protein that was first 
described in the context of renal cell carcinoma, in which 
Fam107a expression is reduced or absent due to promo­
tor hypermethylation [64-66]. Overexpression of
Frijters et al. BMC Genomics 2010, 11:359
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Table 3: Prednisolone-regulated genes associated with 'cell cycle' in literature.
B io lo g ica l p ro ce ss: ce ll cycle
G en e  nam e Sym bo l Fc W T Fc GRdim *
Growth arrest a nd DNA-dam age-inducible 45 gam m a Gadd45g 17.8 2.9
D ual specificity phosphatase 1 D u sp1 8.2 1
Cyclin-dependent kinase inhib itor 1A (P21) C d kn1a 8.1 1
Growth arrest a nd DNA-dam age-inducible 45 beta Gadd45b 5.1 1
Polo-like kinase 3 (Drosophila) Plk3 4.5 1
Retinoblastom a binding protein 8 Rbbp8 4.5 1.3
Bcl2-like 1 Bcl2l 1 3 1.1
Tensin 1 Tn s1 2.6 1.2
Protein tyrosine phosphatase 4a 1 Ptp4a 1 2.3 1.1
Forkhead b o x  O 1 F o x o 1 2.2 1.7
PAX interacting (with transcription-activation dom ain) protein 1 Paxip 1 1.9 1
Forkhead b o x  O3a Foxo3a 1.9 - 1.1
E 1A binding protein p300 Ep300 1.8 1
NIMA (never in m itosis gene a)-related expressed kinase  7 Nek7 1.8 1.1
Cell division cycle 2-like 6 (CDK8-like) Cdc2l6 1.8 1.2
Cell division cycle 40 hom olog (yeast) Cdc40 1.4 1
Cyclin D2 Ccnd2 - 1.5 - 1.2
NIMA (never in m itosis gene a)-related expressed kinase 6 Nek6 - 1.7 - 1.2
CDC28 protein kinase regulatory su bu nit 2 Cks2 -2.3 - 1.3
TSC22 dom ain family, m em ber 1 Tsc22d 1 -4 -2.3
CoPub identified 65 prednisolone-regulated genes in wild type (WT) mice that are associated in literature with the cell cycle (top 20 shown). 
The identified genes share at least 3 publications and have an R-scaled score [34] of at least 35 with keyword 'cell cycle' in M edline abstracts. 
For each gene, the fold change (Fc) in prednisolone versus vehicle-treated WT m ice (Fc WT) is given. Additionally, for each gene also the Fc 
in prednisolone versus vehicle-treated GRdim m ice (Fc GRdim) is shown. *It should be noted that in GRdim m ice these genes did not meet the p- 
value cutoff of 0.01 for significance after correction for m ultiple testing, and are m entioned to illustrate a small effect of prednisolone on gene 
expression in GRdim mice.
Fam107a in Fam107a-negative cell lines leads to growth 
retardation and apoptosis, indicating that Fam107a might 
act as a tumor suppressor [65,67]
We also identified a subset of genes that showed an 
equal induction of gene expression by prednisolone in 
WT and GRdim mice (located on the diagonal black line in 
Figure 4); Dst (Dystonin), a cytoskeletan-interacting pro­
tein postulated to cross-link cytoskeletal filaments and 
thereby maintain cellular integrity [68], Gtf2a2 (General 
transcription factor II A, 2), a subunit of the transcription 
initiation factor TFIIA [69], Agpat6 (1-acylglycerol-3- 
phosphate O-acyltransferase 6), an enzyme involved in 
triglyceride synthesis [70], Marcks (Myristoylated alanine 
rich protein kinase C substrate), cytoskeletal protein 
involved in cell adhesion and cell motility [71], Obfc2a 
(Oligonucleotide/oligosaccharide-binding fold containing 
2A), a single stranded nucleic-acid-binding protein [72], 
and Ppargc1a.
Prednisolone-induced changes in gene expression in 
WT and GRdim mice were validated by Q-PCR for 
Fam107a, Dusp1, Cdkn1a and Car8. Figure 6 shows the 
fold-changes of the selected genes in prednisolone versus 
vehicle-treated W T and GRdim mice. For all four genes, 
the regulation by prednisolone in WT and GRdim mice 
was qualitatively similar to what was found by microarray 
analysis.
Discussion and Conclusion
In this study we performed liver gene expression profiling 
of W T and GRdim mice after prednisolone administration. 
Our aim was to chart the biological processes in the liver 
that are affected by GCs and to study their dependence 
on DNA-binding and dimerization of the GR. CoPub 
keyword enrichment analysis with prednisolone-regu­
lated genes in WT mice showed enrichment of keywords 
associated with glucose, lipid and amino acid metabo­
lism, the cell cycle and apoptosis (Table 1 and Figure 3).
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F ig u re  4 Log2 ratio plot o f p re d n iso lo n e -in d u ced  differential 
gene e xp ressio n  in w ild  type v e rsu s G Rdim mice. Genes on the solid 
black line show an equal induction of differential gene expression by 
prednisolone in wild type (WT) versus GRdim mice. The black-dotted 
line indicates the average slope of the data and shows that the level of 
gene regulation in prednisolone-treated GRdim mice is 33% of that ob­
served in WT mice. A subset of genes that show obvious differences in 
the magnitude of regulation by prednisolone in WT versus GRdim mice 
is highlighted, as well as genes that show equal magnitude of regula­
tion in WT versus GRdim mice.
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F ig u re  5 In ten sity  p ro files o f Plk3, D u s p l,  G add45b, C d k n 1a, 
Fo xo3a  and F a m 107a  in veh ic le  and p redn isolo ne-treated w ild 
type and GRdim mice. Several genes were identified that showed dif­
ferences between prednisol one-treatment in wild type (WT) and GRdim 
mice. Amongst those genes are Plk3, Dusp 1, Gadd45b, Cdkn 1a, Foxo3a 
and F a m 107a were differential regulated in prednisolone-treated WT 
mice, but not in GRdim mice. White bars represent vehicle-treated mice, 
whereas grey bars represent prednisolone-treated mice. Symbols; Tri­
angles: female mice, Bullets: male mice.
This is in agreement with cellular processes known to be 
affected by GCs [73,74]. Interestingly, the forkhead tran­
scription factors Foxo1 and Foxo3a are regulators of these 
cellular processes and induced by prednisolone in WT 
mice. Together with the observation that a subset of the 
prednisolone-induced genes are Foxo1 and Foxo3a target 
genes and are similarly regulated in Foxo1 and Foxo3a 
expression profiling experiments [54,59,60], this suggests 
that the GR synergizes with these transcription factors in 
mouse liver to control lipid and glucose metabolism and 
the cell cycle. This concept is further supported by the 
recent finding that the MurFl (Muscle RING finger 1) 
promoter contains adjacent binding sites for the GR and 
Foxo transcription factors and is synergistically activated 
when both are co-expressed [75]. However, it is likely that 
a subset of the prednisolone-induced genes is under 
direct control of Foxo1 and Foxo3a without the need for 
synergy with the GR. Other studies, addressing small 
gene sets or individual genes, had also identified a role for 
Foxo1 and Foxo3a in GR-induced gene expression [58,75­
77].
The list of differentially regulated genes by predniso­
lone in WT mice overlaps with that of an earlier study by
F ig u re  6 V a lid a tio n  o f m icroarray-o btain ed gen e e xp ressio n  by 
Q-PCR. The relative expression of F a m 107a, D usp1, Cdkn 1a and Car8 in 
prednisolone-treated versus vehicle-treated wild type (WT) and GRdim 
mice was validated by Q-PCR. Differences in expression between two 
samples were calculated by the 2AACt method [103,104]. Mean differ­
ences in gene expression between WT and GRdim mice were analyzed 
using the Student's t-test. No expression was observed for F a m 107a 
and Cdkn 1a in vehicle and prednisolone-treated GRdim mice (Ct > 30). 
Asterisks denote p-values as follows: *p < 0.05, **p < 0.01 and ***p < 
0.001.
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Phuc Le et al, which combined chromatin immunopre- 
cipitation (ChIP) data with gene expression data to iden­
tify direct GR target genes in mouse liver [78]. Most of 
the genes found in our study displayed the same up and 
downregulation of gene expression, such as Tat, Foxol 
and FkbpS that are upregulated and Adipor2, CCAAT/ 
enhancer binding protein alpha (C/EBPa) and Tkt that are 
downregulated. From a candidate gene set of 302 genes, 
Phuc Le et al identified metabolism, cell proliferation and 
programmed cell death as important processes in their 
GO-term analysis, which is in agreement with our find­
ings.
Interestingly, in contrast to our study, Phuc Le et al did 
not observe upregulation of bona fide GR target genes, 
such as Pck and Igfpb in fed CD1 mice and explain this by 
lack of response due to a potential inhibition by insulin 
signaling in the fed state [79]. The fact that we observed 
upregulation of these genes indicates that in our experi­
mental setup, which differs in several aspects from the 
setup used by Phuc Le et al, such as mouse strain used for 
the study, GC dosage and the fed state of the mice, the 
inhibitory effects of fed-induced insulin signaling do not 
play a role.
The overall induction of gene expression was strongly 
reduced in prednisolone-treated GRdim mice compared to 
WT mice (Figure 4). Nevertheless, in many cases residual 
gene induction by prednisolone was still observed. This 
indicates that GR dimerization is indeed an important 
mechanism for activation of these genes, although some 
regulation can take place even in the absence of GR 
homodimers. In fact, GR monomers are in principle 
capable of binding to GC response elements (GREs) and 
evoking a basal induction of gene expression. However, 
due to the lack of cooperative binding they are less potent 
than GR homodimers. This is in line with the regulation 
reported for Pnmt (Phenylethanolamine-N-methyltrans- 
ferase) and Amy2 in which binding of GR monomers to 
GREs or a GRE half-site (i.e. only one-half of the classical 
palindrome) was sufficient to confer induction by GCs 
[80,81]. In case of the Pnmt gene, multiple GRE half-site 
have been identified in the promoter region allowing 
receptor clustering and thereby stable binding of GR 
monomers independent of the DNA-binding domain 
(DBD) interface [80]. This also explains why expression of 
the Pnmt gene is not compromised in GRdim mice despite 
the lack of GR dimer formation [21]. Another explanation 
for the residual gene induction by prednisolone in GRdim 
mice is that the mutant GR still forms homodimers but 
that these are far less stable than in WT mice.
A recent study showed that the specific sequence of a 
GRE differently affects the conformation of the GR and 
thereby its activity towards specific target genes [82]. 
Mutation analysis of overexpressed GR domains that are 
involved in transcriptional activation, namely the
dimerization region in the DBD (Dim) as well as AF1 and 
AF2 (activation function 1 and 2), showed that the depen­
dency on each of them was specific for the sequence of 
the GR binding site and that genes differed in their 
dependence on dimerization [82]. The fold induction of 
Tat and FkbpS by dexamethasone in the Dim mutant was 
around 30% for Tat and 50% for FkbpS of that for WT 
GR, which is in gross agreement with our own observa­
tions in vivo (Figure 4).
The effect of the GRdim mutation was found in all major 
pathways that were induced by prednisolone, i.e. for 
genes in inflammatory pathways, gluconeogenesis and 
cell cycle. Moreover, the attenuating effect of the GRdim 
mutation was found for genes that were upregulated as 
well as for genes that were downregulated by predniso­
lone. This suggests that genes, which fail to be repressed 
by prednisolone in GRdim mice, are either regulated 
through GR binding to negative GRE elements (nGREs) 
or indirectly regulated via other GR target genes. Inter­
estingly, analysis of the magnitude of gene regulation by 
prednisolone in WT mice compared to GRdim mice 
showed that the cell cycle-related genes are more depen­
dent on the dim interface than genes related to gluconeo- 
genesis (Table 2 and 3). This can also be appreciated in 
Figure 4; several genes that are on the x-axis (i.e. show no 
differential gene expression upon prednisolone treatment 
in GRdim mice), are cell cycle-related.
We identified several genes that showed strong upregu- 
lation by prednisolone in GRdim mice compared to WT 
mice, such as Amy2, Car8 and Zdhhc23, and several 
genes that showed equal induction of gene expression by 
prednisolone in WT and GRdim mice, amongst them are 
Dst and Ppargcla (Figure 4). These genes are potential 
candidates for having GRE half-sites in their promotor 
regions, which could explain why these genes show equal 
or even higher induction of gene expression by predniso­
lone compared to WT mice. As mentioned earlier, the 
presence of GR half-sites in the promotor region for 
Amy2 was indeed experimentally confirmed [81]. For the 
other genes however, we did not find literature evidence 
for the presence of GR half-sites in their promotor 
regions. Therefore, follow-up studies on these genes to 
determine the functional GRE sites in their regulatory 
region would be of interest to study the significance of 
dimer-interface independent GRE binding. Genes that 
showed equal or stronger upregulation by prednisolone 
in GRdim mice compared to WT mice can also be second­
ary response genes; under transcriptional control of tran­
scription factors other than the GR. Keyword enrichment 
analysis performed with this set of genes did not identify 
enrichment for a particular cellular process.
We identified several genes that are absolutely depen­
dent on GR dimerization for the induction of gene
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expression by prednisolone, such as Cdknla, Gadd4Sb, 
Duspl, Plk3 and Foxo3a (Figure 4). Interestingly, all of 
these have a strong relationship with p53: some are under 
direct transcriptional control of p53 (Cdknla [83], 
Gadd4Sb [84] and Duspl [48]) or physically interact with 
p53 (Foxo3a [85,86] and Plk3 [87]). The cellular responses 
mediated by Foxo3a and p53 are highly similar, share 
some of their target genes (e.g. Cdknla and Gadd4Sb) 
and use similar mechanisms to regulate post-transla­
tional modification [51,88]. Therefore, Foxo3a and p53 
can be regarded as partners that positively as well as neg­
atively regulate each other, depending on the context [51]. 
This observation might indicate that GC-induced activa­
tion of Foxo3a and/or p53 is hampered in GRdim mice. In 
line with this hypothesis Foxo3a was recently shown to be 
required for GC-induced apoptosis in lymphocytes [89]. 
Interestingly, this process is defective in GRdim mice high­
lighting a possible link between the GR, Foxo3a and 
induction of lymphocyte apoptosis [21].
Faml07a showed the largest induction of gene expres­
sion by prednisolone in WT mice (Figure 4 and 5). Analy­
sis of protein-protein interactions revealed that Fam107a 
interacts with Tada2a [90,91], a protein that together with 
binding partner Tada3a (Transcriptional adaptor 2 and 3 
alpha) are core proteins of the histone acetyltransferase 
(HAT) complex [92]. HAT complexes are involved in 
chromatin structure modification for initiation of gene 
transcription, but can also acetylate non-histone proteins 
to modify their activity and stability [92,93]. Interestingly, 
Fam107b a paralog of Fam107a with 84% protein similar­
ity (not regulated in mouse liver by prednisolone) was 
shown to interact with Tada3a [94].
The observation that Fam107a inhibits cell prolifera­
tion and induces apoptosis when overexpressed [65,67], 
suggests that Fam107a, like Foxo3a, Dusp1, Gadd45b, 
Cdkn1a and Plk3 play a role in regulating the cell cycle. 
Furthermore, the association of Fam107a with a core pro­
tein of the HAT complex might indicate that Fam107a 
may serve as a cofactor in the transcription machinery 
complex.
The activity and function of Foxo3a and p53 are 
strongly modulated by acetylation [51,88,95]. Hence, 
Faml07a is an interesting candidate gene for follow up 
experiments to study whether it modulates GR-induced 
gene expression and/or acetylation of GR-associated 
transcription factors such as Foxo3a, p53, C/EBPa and C/ 
EBPp (CCAAT/enhancer binding protein, beta).
For a more comprehensive view on GC regulated pro­
cess in the liver, experiments with multiple time points, 
different doses of GCs and using one or more inflamma­
tory stimuli, could be considered.
Methods
Animals
All mice (WT and GRdim; Balb/c) were bred at the Insti­
tute of Virology and Immunobiology at the University of 
Wurzburg. In total 24 mice (8 male WT, 4 female WT, 8 
male GRdim and 4 female GRdim) were included in the 
study. Mice were treated subcutaneously with 1 mg/kg 
prednisolone (5% DMSO and 5% Chremophor in mani- 
tol, 10 ml/kg) once and sacrificed 150 minutes later by 
cervical dislocation, which was approved by the responsi­
ble authorities in Bavaria (Regierung von Unterfranken). 
All experiments were performed in the morning between 
9 and 10 AM. The mice were exposed to a regular dark- 
light-cycle (lights on between 6 AM and 6 PM) and had 
access to water and food ad libitum at any time.
RNA isolation
Liver biopsy specimens were collected into aluminum 
containers, snap freezed in liqN2 and stored at -80°C 
before use. RNA isolation was done using Trizol, followed 
by RNeasy clean-up to enhance the A260/A230 ratio. RNA 
quantity and quality was determined using the NanoDrop 
Spectrophotometer and Agilent Bioanalyzer. For all sam­
ples subjected to microarray hybridization, the RIN 
(RNA integrity number) was 9.0 - 10.
Microarray data processing
Processed RNA samples were hybridized on GeneChip 
Mouse Genome 430 2.0 arrays (MOE430-2) from 
Affymetrix [96]. Processing and downstream statistical 
analysis of the microarray data was done using the R Sta­
tistics package [97]. Data were normalized using the 
gcrma algorithm, pair-wise ratios between treatments 
were built using the limma package and annotation for 
the probe sets was derived from the mouse4302 library, 
all as provided in BioConductor [98]. In all contrast 
matrices, a correction for gender type was applied. Data 
were deposited in the NCBI Gene Expression Omnibus 
(GEO), accession number GSE21048.
Keyword enrichment analysis
Keyword enrichment analysis on the microarray data was 
performed using CoPub [34] with default settings as pro­
vided by the web server [99]. The literature-network 
between enriched keywords and genes (nodes) and their 
co-publications (edges) were visualized using Cytoscape 
software [100,101].
Validation of microarray results with Q-PCR
Total RNA (1 |jg) was reverse transcribed using a com­
mercially available cDNA synthesis kit (iScript, BioRad 
Laboratories, Hercules, CA, USA). Q-PCR was per­
formed by SYBR Green-based quantification according to
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the manufacturer's protocol (Applied Biosystems, Foster 
City, CA, USA). Primers were developed for Fam107a 
(Family with sequence similarity 107, member a; 
Fw:TCATCAAACCCAAGAAGCTG; Rev: CTCAG- 
GCTTGCTGTCCATAC), Car8 (Carbonic anhydrase 8; 
Fw: CACACCATTCAAGTCATCCTG; Rev: ACCA- 
CGCTGGTTTTCTCTTC), Cdkn1a (Cyclin-dependent 
kinase inhibitor 1a; Fw: TCTTGCACTCTGGTGTCT- 
GAG; Rev: ATCTGCGCTTGGAGTGATAG) and Dusp1 
(Dual specificity phosphatase 1; Fw: GTGCCTGACAGT- 
GCAGAATC; Rev: CCAGGTACAGGAAGGACAGG) 
using Primer3 [102]. All primer pairs were exon-span­
ning. The gene Azgp1 (alpha-2-glycoprotein 1, zinc-bind­
ing; Fw: AAGGAAAGCCAGCTTCAGAG; Rev: 
ACCAAACATTCCCTGAAAGG) was chosen as endog­
enous control since the expression arrays did not show 
any differences in expression of this gene between the 
two experimental groups (WT vs GRdim). PCR products 
were selected to be between 80 and 120 bp long. Samples 
were run on the 7500 Fast Real-Time PCR System 
(Applied Biosystems) using the following protocol: 10 
min. denaturation at 95°C, and 40 cycles of 15 sec. dena­
turation at 95°C, 60 sec. annealing and extension at 60°C. 
All primer pairs were validated in triplicate using serial 
cDNA dilutions. Primer pairs that were 100 ± 10% effi­
cient, which implies a doubling of PCR product in each 
cycle, were used to quantify mRNA levels. Threshold 
cycle numbers (referred to as Ct) were obtained using the 
7900 HT System SDS software version 2.3 (Applied Bio­
systems). All samples were measured for three times and 
samples with a standard deviation (SD) larger than 0.5 
were excluded from the analysis. The relative quantity 
(RQ) of the gene-specific mRNA was calculated from the 
average value of the ACt (target gene Ct - endogenous 
control gene Ct) for each of the 24 analyzed samples. Dif­
ferences in expression between two samples were calcu­
lated by the 2AACt method [103,104]. For Q-PCR, mean 
differences in expression between groups were analyzed 
using the Student's t-test. A p-value of < 0.05 was consid­
ered statistically significant in each situation.
Protein - protein interaction data
Protein-protein interaction data were retrieved from the 
Biological General Repository for Interaction Datasets 
(BioGRID) database [105,106].
Additional file 2 Differentially regulated probe sets in liver of predni­
solone-treated versus vehicle-treated GRdimmice. Prednisolone treat­
ment resulted in a significant differential regulation of 34 probe sets in 
GRdim mice (29 upregulated and 5 downregulated; p-value < 0.01). The 
table shows the Affymetrix probe set identifiers of the differentially regu­
lated probe sets, full gene names, gene symbols and the fold changes.
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